Portfolio Building Block World Pharma and Biotech Index ETF
PBPH - ETF AI Analysis
Top Page
Portfolio Building Block World Pharma and Biotech Index ETF (PBPH)
PBPH, the Portfolio Building Block World Pharma and Biotech Index ETF, has a solid overall rating driven mainly by large positions in strong global pharma leaders like Merck, AstraZeneca, Johnson & Johnson, Novartis, and Gilead, all benefiting from robust financial performance, positive earnings outlooks, and healthy product pipelines. However, some key holdings such as Eli Lilly, AbbVie, Amgen, Roche, and Pfizer face valuation, leverage, or growth challenges that slightly weigh on the fund’s rating, and the main risk is its heavy concentration in the pharmaceutical and biotech sector, which can make performance more sensitive to industry-specific news and regulation.
PBPH vs. SPDR S&P 500 ETF (SPY)
- AUM
- 1.38B
- Region
- Developed Markets
- Expense Ratio
- 0.13%
- Beta
- 0.10
- Issuer
- Portfolio Building Block
- Inception Date
- Nov 24, 2025
- Dividend Yield
- 0.07%
- Asset Class
- Equity
- Index Tracked
- BITA Global Pharma and Biotech Select Index - Benchmark TR Net
PBPH Summary
PBPH is an ETF that follows the BITA Global Pharma and Biotech Select Index, focusing on healthcare companies that earn most of their money from medicines and biotechnology. It holds many well-known names such as Eli Lilly and Johnson & Johnson, along with other major drug makers from the U.S. and abroad. Investors might consider PBPH if they want simple, one-click diversification across leading pharma and biotech firms and believe in long-term growth from new treatments and medical innovations. A key risk is that it is heavily concentrated in healthcare, so its value can rise or fall sharply with changes in drug pricing, regulation, or industry news.
How much will it cost me?
The Portfolio Building Block World Pharma and Biotech Index ETF (PBPH) has an expense ratio of 0.13%, meaning you’ll pay $1.30 per year for every $1,000 invested. This is lower than average because it is a passively managed fund that tracks an index, which typically keeps costs down.
What would affect this ETF?
The PBPH ETF could benefit from increased global healthcare spending, advancements in biotechnology, and demand for innovative treatments, especially as its top holdings include leading pharmaceutical companies like Eli Lilly and Johnson & Johnson. However, it may face challenges from regulatory changes, patent expirations, or economic downturns that could reduce healthcare budgets and impact the performance of its holdings. Additionally, its focus on developed markets may limit exposure to growth opportunities in emerging economies.
PBPH Top 10 Holdings
PBPH is essentially a who’s who of global Big Pharma, with Eli Lilly, Johnson & Johnson, AbbVie, and Merck setting the tone. Lilly and AbbVie have been rising on the back of strong pipelines, while Merck and Amgen look like steady engines of growth rather than flashy high-fliers. AstraZeneca and Gilead add more punch, though their performance has been a bit more mixed, occasionally losing steam. With almost all exposure in large healthcare names across the U.S. and Europe, the fund is tightly focused on pharma and biotech heavyweights driving long-term returns.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 17.05% | $227.86M | $1.34T | 41.12% | 72Outperform | |
| Johnson & Johnson | 9.51% | $127.18M | $682.52B | 46.35% | 78Outperform | |
| AbbVie | 7.34% | $98.05M | $520.47B | 27.01% | 66Neutral | |
| Merck & Company | 5.12% | $68.41M | $362.27B | 59.00% | 80Outperform | |
| Roche Holding AG | ― | ― | ― | ― | 73Outperform | |
| AstraZeneca | ― | ― | ― | ― | 80Outperform | |
| Amgen | 4.36% | $58.34M | $252.64B | 38.59% | 77Outperform | |
| Novartis AG | 4.09% | $54.61M | CHF 245.70B | 26.78% | 80Outperform | |
| Gilead Sciences | 4.05% | $54.09M | $208.31B | 34.25% | 78Outperform | |
| Pfizer | 3.23% | $43.18M | $164.33B | 12.02% | 74Outperform |
PBPH Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PBPH, the sentiment is Positive. The current price of 31.62 is above the 20-day moving average (MA) of 30.72, above the 50-day MA of 29.30, and above the 200-day MA of 27.14, indicating a bullish trend. The MACD of 0.72 indicates Negative momentum. The RSI at 65.31 is Neutral, neither overbought nor oversold. The STOCH value of 72.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PBPH.
PBPH Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $31.62 | $31.00(-1.96% Downside) | $1.38B | 0.13% | 70Neutral | |
| $58.72 | $84.13(43.27% Upside) | $9.55B | 0.68% | 64Neutral | |
| $31.23 | $40.91(30.98% Upside) | $2.99B | 0.68% | 58Neutral | |
| $36.16 | $40.48(11.94% Upside) | $491.69M | 0.13% | 70Outperform | |
| $28.43 | $37.03(30.25% Upside) | $286.85M | 0.49% | 61Neutral | |
| $26.14 | $35.85(37.16% Upside) | $5.27M | 0.59% | 64Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PBPH | Portfolio Building Block World Pharma and Biotech Index ETF | 31.62 | 6.57 | 26.21% | |
| AIQ | Global X Artificial Intelligence & Technology ETF | 58.72 | 9.26 | 18.73% | |
| BOTZ | Global X Robotics & Artificial Intelligence ETF | 31.23 | -2.93 | -8.56% | |
| PBOG | Portfolio Building Block Integrated Oil and Gas and Exploration and Production Index ETF | 36.16 | 11.31 | 45.51% | |
| SRVR | Pacer Benchmark Data & Infrastructure Real Estate SCTR ETF | 28.43 | 0.75 | 2.72% | |
| THNR | Amplify Weight Loss Drug & Treatment ETF | 26.14 | 1.55 | 6.32% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
